These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 37925066

  • 1. Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome.
    Gunter SJ, Kim EJ.
    J Invest Dermatol; 2024 Apr; 144(4):855-861.e1. PubMed ID: 37925066
    [Abstract] [Full Text] [Related]

  • 2. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
    Franceschi J, Ehret M, Visseaux L, Durlach A, Barbe C, Durot É, Grange F.
    Acta Derm Venereol; 2022 Mar 22; 102():adv00676. PubMed ID: 35083494
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators.
    Lancet Oncol; 2018 Sep 22; 19(9):1192-1204. PubMed ID: 30100375
    [Abstract] [Full Text] [Related]

  • 6. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
    Jfri A, Smith JS, Larocca C.
    J Am Acad Dermatol; 2023 May 22; 88(5):1164-1166. PubMed ID: 36481378
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
    Querfeld C, Zain J, Rosen ST.
    Cancer Treat Res; 2019 May 22; 176():225-248. PubMed ID: 30596221
    [Abstract] [Full Text] [Related]

  • 9. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
    Muszbek N, Remak E, Xin Q, McNamara L, Jones T.
    J Comp Eff Res; 2023 Jul 22; 12(7):CER. PubMed ID: 37338181
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
    Quadri I, Reneau JC, Hanel W, Chung CG.
    Front Immunol; 2023 Jul 22; 14():1291259. PubMed ID: 38022633
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
    Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC, International Society for Cutaneous Lymphomas, United States Cutaneous Lymphoma Consortium, Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
    J Clin Oncol; 2011 Jun 20; 29(18):2598-607. PubMed ID: 21576639
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Current therapeutic options in Mycosis fungoides and Sézary syndrome].
    Albrecht JD, Nicolay JP.
    Hautarzt; 2022 Jan 20; 73(1):75-85. PubMed ID: 34988613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.